Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 20/9/2020
SIETES contiene 93097 citas

 1 a 20 de 175 siguiente >>
Presentar resultados
Seleccionar todas
2.Enlace a cita original Cita con resumen
Savarese G, Costanzo P, Cleland JGF, Vassallo E, Ruggiero D, Rosano G, Perrone-Filardi P. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol 2013;61:131-42. [Ref.ID 94624]
3. Cita con resumen
Krum H, Abraham WT. Heart failure. Lancet 2009;373:941-55. [Ref.ID 85474]
Tatsioni A, Gonitsis NG, Ioannidis JPA. Persistence of contradicted claims in the literature. JAMA 2007;298:2517-26. [Ref.ID 81746]
Sawka AM, Ray JG, Yi Q, Josse RG, Lonn E. Randomized clinical trial of homocysteine level-lowering therapy and fractures. Arch Intern Med 2007;167:2136-8. [Ref.ID 81528]
7. Cita con resumen
Snoep JD, Hovens MMC, Eikenboom JCJ, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events. A systematic review and meta-analysis. Arch Intern Med 2007;167:1593-9. [Ref.ID 80892]
8.Tiene citas relacionadas Cita con resumen
Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007;370:591-603. [Ref.ID 80810]
9.Tiene citas relacionadas
Anónimo. Hypertension: uncontrolled and conquering the world. Lancet 2007;370:539. [Ref.ID 80796]
10.Tiene citas relacionadas
Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Authors reply. Lancet 2007;370:24-5. [Ref.ID 80491]
11.Tiene citas relacionadas
Mascitelli L, Pezzetta F. Renin-angiotensin system and cardiovascular risk. Lancet 2007;370:24. [Ref.ID 80490]
12.Tiene citas relacionadas
Strauss-MH, Hall A. Renin-angiotensin system and cardiovascular risk. Lancet 2007;370:23-4. [Ref.ID 80489]
13.Tiene citas relacionadas Cita con resumen
Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BMW. Renin-angiotensin systema and cardiovascular risk. Lancet 2007;369:1208-19. [Ref.ID 79756]
14. Cita con resumen
Elliott WJ, Myer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007;369:201-7. [Ref.ID 78904]
16.Tiene citas relacionadas Cita con resumen
Remuzzi G, Ruggenenti P. Overview of randomised trials of ACE inhibitors. Lancet 2006;368:555-6. [Ref.ID 77807]
Thornley-Brown D, Wang X, Wright Jr JT, Randall OS, Miller ER, Lash JP, Gassman J, Contreras G, Appel LJ, Agodoa LY, Cheek D, for the African American Study of Kidney Disease and Hypertension Study Group. Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease. Arch Intern Med 2006;166:797-805. [Ref.ID 76708]
18. Cita con resumen
Danchin N, Cucherat M, Thuillez C, Durand E, Kadri Z, Steg PG. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction. Arch Intern Med 2006;166:787-96. [Ref.ID 76707]
19.Tiene citas relacionadas
Loscalzo J. Homocysteine trials - clear outcomes for complex reasons. N Engl J Med 2006;354:1629-32. [Ref.ID 76666]
20.Tiene citas relacionadas Cita con resumen
Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K, for the NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-88. [Ref.ID 76664]
Seleccionar todas
 1 a 20 de 175 siguiente >>